Literature DB >> 19004414

MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.

José Carlos Bouso1, Rick Doblin, Magí Farré, Miguel Angel Alcázar, Gregorio Gómez-Jarabo.   

Abstract

The purpose of this study was to investigate the safety of different doses of MDMA-assisted psychotherapy administered in a psychotherapeutic setting to women with chronic PTSD secondary to a sexual assault, and also to obtain preliminary data regarding efficacy. Although this study was originally planned to include 29 subjects, political pressures led to the closing of the study before it could be finished, at which time only six subjects had been treated. Preliminary results from those six subjects are presented here. We found that low doses of MDMA (between 50 and 75 mg) were both psychologically and physiologically safe for all the subjects. Future studies in larger samples and using larger doses are needed in order to further clarify the safety and efficacy of MDMA in the clinical setting in subjects with PTSD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19004414     DOI: 10.1080/02791072.2008.10400637

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  41 in total

1.  Comment on the letter by Green, Gabrielsson, Marsden, and Fone, MDMA: on the translation from rodent to human dosing.

Authors:  Rafael de la Torre; Elena Puerta; Norberto Aguirre
Journal:  Psychopharmacology (Berl)       Date:  2009-01-16       Impact factor: 4.530

Review 2.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

3.  Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.

Authors:  Stephen J Kish; Jason Lerch; Yoshiaki Furukawa; Junchao Tong; Tina McCluskey; Diana Wilkins; Sylvain Houle; Jeffrey Meyer; Emanuela Mundo; Alan A Wilson; Pablo M Rusjan; Jean A Saint-Cyr; Mark Guttman; D Louis Collins; Colin Shapiro; Jerry J Warsh; Isabelle Boileau
Journal:  Brain       Date:  2010-05-17       Impact factor: 13.501

Review 4.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 5.  Pharmacological treatment of anxiety disorders: current treatments and future directions.

Authors:  Frank J Farach; Larry D Pruitt; Janie J Jun; Alissa B Jerud; Lori A Zoellner; Peter P Roy-Byrne
Journal:  J Anxiety Disord       Date:  2012-08-15

6.  MDMA does not alter responses to the Trier Social Stress Test in humans.

Authors:  Anya K Bershad; Melissa A Miller; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2017-04-21       Impact factor: 4.530

7.  Neurochemical binding profiles of novel indole and benzofuran MDMA analogues.

Authors:  Jakob A Shimshoni; Ilan Winkler; Ezekiel Golan; David Nutt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-20       Impact factor: 3.000

8.  MDMA alters emotional processing and facilitates positive social interaction.

Authors:  Margaret C Wardle; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2014-04-12       Impact factor: 4.530

9.  Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use.

Authors:  Eugene A Kiyatkin; Albert H Kim; Ken T Wakabayashi; Michael H Baumann; Yavin Shaham
Journal:  J Neurosci       Date:  2014-06-04       Impact factor: 6.167

Review 10.  Progress and promise for the MDMA drug development program.

Authors:  Allison A Feduccia; Julie Holland; Michael C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2017-11-20       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.